文献速递衰弱、肌少症与跌倒老年慢病共病管理

衰弱作为降糖药物观察性研究中未测量混杂因素的评估

Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2019-01-01

该回顾性队列研究纳入500例住院退伍军人,评估衰弱是否混杂降糖方案与死亡的关系,以及行政和临床电子健康记录数据对衰弱的解释程度。结果显示衰弱与降糖方案及死亡相关,可能混杂该关系;常用数据评估死亡风险中等,加入衰弱指数改善有限。

要点

  • 衰弱指数每增加0.05与死亡风险增加相关(HR 1.45,95%CI 1.32,1.60)。
  • 不同降糖方案间衰弱指数存在差异(p < .001)。
  • 行政和临床电子健康记录数据评估死亡风险中等,加入衰弱指数改善有限。

核心结论

  • 衰弱与降糖方案及死亡相关,可能混杂降糖方案与死亡的关系。
  • 常用行政和临床电子健康记录数据评估死亡风险表现中等,加入衰弱指数改善有限。

研究设计与样本

  • 单中心退伍军人健康管理医疗系统的回顾性队列研究,纳入500例住院(多数因心力衰竭)并接受2型糖尿病治疗的退伍军人。
  • 使用改良衰弱指数(FI,>0.21为衰弱)测量衰弱,从行政来源获取降糖方案和死亡时间。
  • 采用逐步Cox比例风险回归估计死亡时间,比较不同降糖方案的衰弱指数。

主要发现

  • 衰弱指数中位数为0.22(四分位距0.18,0.27)。
  • 不同降糖方案间衰弱指数存在差异(p < .001)。
  • 衰弱指数增加0.05与死亡风险增加相关(HR 1.45,95%CI 1.32,1.60)。
  • 包含人口学、行政和临床电子健康记录数据的Cox模型c统计量为0.70,加入衰弱指数后为0.72,改善有限。

临床怎么用

  • 在评估降糖药物与死亡关系的观察性研究中,应考虑衰弱作为潜在混杂因素。
  • 研究设计和分析技术有助于减少衰弱所致的潜在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown whether observational studies evaluating the association between antidiabetic medications and mortality adequately account for frailty. Our objectives were to evaluate if frailty was a potential confounder in the relationship between antidiabetic medication regimen and mortality and how well administrative and clinical electronic health record (EHR) data account for frailty. METHODS: We conducted a retrospective cohort study in a single Veterans Health Administration (VHA) healthcare system of 500 hospitalizations-the majority due to heart failure-of Veterans who received regular VHA care and initiated type 2 diabetes treatment from 2001 to 2008. We measured frailty using a modified frailty index (FI, >0.21 frail). We obtained antidiabetic medication regimen and time-to-death from administrative sources. We compared FI among patients on different antidiabetic regimens. Stepwise Cox proportional hazards regression estimated time-to-death by demographic, administrative, clinical EHR, and FI data. RESULTS: Median FI was 0.22 (interquartile range 0.18, 0.27). Frailty differed across antidiabetic regimens (p < .001). An FI increase of 0.05 was associated with an increased risk of death (hazard ratio 1.45, 95% confidence interval 1.32, 1.60). Cox proportional hazards model for time-to-death including demographic, administrative, and clinical EHR data had a c-statistic of 0.70; adding FI showed marginal improvement (c-statistic 0.72). CONCLUSIONS: Frailty was associated with antidiabetic regimen and death, and may confound that relationship. Demographic, administrative, and clinical EHR data, commonly used to balance differences among exposure groups, performed moderately well in assessing risk of death, with minimal gain from adding frailty. Study design and analytic techniques can help minimize potential confounding by frailty in observational studies.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Presley CA, Chipman J, Min JY, et al. Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications. J Gerontol A Biol Sci Med Sci. 2019. PMID: 30256914. doi:10.1093/gerona/gly224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。